FOI_8419

Internal Reference Number: FOI_8419

Date Request Received: 03/02/2025 00:00:00

Date Request Replied To: 13/02/2025 00:00:00

This response was sent via: By Email

Request Summary: new biologic and targeted medications

Request Category: Researcher


Question Number 1: How many patients were treated in January 2025 (or latest available month) by the Dermatology department with the following drugs: • Abrocitinib (Cibinqo) • Baricitinib (Olumiant) • Dupilumab (Dupixent) • Lebrikizumab (Ebglyss) • Omalizumab (Xolair) • Tralokinumab (Adtralza) • Upadacitinib (Rinvoq)

Answer To Question 1: In January 2025: • Abrocitinib (Cibinqo) <5 • Baricitinib (Olumiant) 0 • Dupilumab (Dupixent) 21 • Lebrikizumab (Ebglyss) <5 • Omalizumab (Xolair) <5 • Tralokinumab (Adtralza) 5 • Upadacitinib (Rinvoq) <5

Question Number 2: How many patients were treated in January 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: • Benralizumab (Fasenra) • Dupilumab (Dupixent) • Mepolizumab (Nucala) • Omalizumab (Xolair) • Reslizumab (Cinqaero) • Tezepelumab (Tezspire)

Answer To Question 2: How many patients were treated in January 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: • Benralizumab (Fasenra) - 0 • Dupilumab (Dupixent) - 0 • Mepolizumab (Nucala) - 0 • Omalizumab (Xolair) - 5 • Reslizumab (Cinqaero) - 0 • Tezepelumab (Tezspire) - 0

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.